Matica Enterprises Inc. (CSE:MMJ;FWB:39N;OTCPink:MQPXF) (“Matica” or the “Company”) is pleased to announce that it has retained Maricom Inc. (“Maricom”) to provide investor relations services to the Company in compliance with regulatory guidelines.

Matica Engages Maricom


Maricom is a Quebec-based communications firm focused on providing fully bilingual investor relations services to build and create awareness for companies in all stages of development in every key network. The firm brings unique expertise in the cannabis sector and will be providing a range of services, including presenting Matica’s business and milestones to a network of investment advisors, analysts and institutional fund managers.

Maricom will work closely with Matica to develop and deploy a comprehensive capital markets strategy and campaign. Activities will include developing precise messaging, distributing that message cost-effectively and optimizing the Company’s branding, website and social media presence bilingually with Maricom’s graphic design and social media team.

Under the terms of engagement, Maricom has been retained for a six and a half period starting December 15th 2018 at $3,000 per month. The Company has also granted 500,000 stock options exercisable at $0.10 to Maricom.

About Maricom

Maricom is a Quebec-based firm who provide a fully bilingual investor relations service. Their focus is mainly in Quebec via a strong French network as well as extensive ties and direct relationships with Bay Street to ensure their clients have strong exposure throughout Canada and beyond.

About Matica

Matica is a multi-faceted, innovative company in the Quebec cannabis space. Matica has a 70% interest in RoyalMax Biotechnology Canada Inc. (“RoyalMax”). RoyalMax was recently granted a cultivation licence by Health Canada for the fully completed 10,000 square foot production facility in Dorval, Quebec. RoyalMax is one of only 11 Licensed Producers in the Province of Quebec. Matica is also building 1,000,000 square feet of greenhouses on a 181 acre property in the township of Hemmingford, south of Montreal. Matica has entered into an agreement to acquire a 40% position in Yunify Natural Technologies, a Quebec based health and personal care research and innovation company.

For more information on Matica Enterprises please visit the website at: www.maticaenterprises.com.

On behalf of the Board of Directors

MATICA ENTERPRISES INC.

Boris Ziger

Boris Ziger, CEO & Chairman

The Company’s public filings are available for review at www.sedar.com and www.thecse.com.

For further information, please contact Remy Scalabrini, Investor Relations, at:

Telephone: 1(888) 585-6274

E-mail: info@maticaenterprises.com

Website: www.maticaenterprises.com

Disclaimer for Forward-Looking Information

Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Corporation assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Corporation. Additional information identifying risks and uncertainties is contained in the Corporation’s filings with the Canadian securities regulators, which filings are available at www.sedar.com.

This news release contains statements about the Company’s information that may be made available on the S&P Capital IQ Corporation Records Listing Program and the business of Matica that are forward-looking in nature and as a result, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. We seek Safe Harbor.

Click here to connect with Matica Enterprises Inc. (CSE:MMJ;FWB:39N;OTCPink:MQPXF) for an Investor Presentation. 

Source: www.thenewswire.com

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less